Extended follow-up following "full-metal jacket" percutaneous coronary interventions with drug-eluting stents
- PMID: 24550090
- DOI: 10.1002/ccd.25455
Extended follow-up following "full-metal jacket" percutaneous coronary interventions with drug-eluting stents
Abstract
Objectives: To report very long-term follow-up of "Full-Metal Jacket" (FMJ) percutaneous coronary interventions (PCI) in long-diffuse coronary lesions with drug-eluting stents (DES).
Background: PCI for long-diffuse lesions may result in FMJ, which is not preferred by some operators due to long-term risk of restenosis and stent thrombosis. The data on long-term follow-up of patients with FMJ are limited and would be useful in understanding the safety and feasibility of such a strategy.
Methods: Between April 2002 and March 2007, 274 patients (297 lesions in native coronary arteries) underwent PCI utilizing DES. FMJ was described as lesions requiring ≥ 60 mm of continuous stent. The measured endpoints were cardiac death, target-vessel myocardial infarction (MI), target lesion revascularization (TLR), target-vessel revascularization (TVR), and major adverse cardiac events (MACE) defined as composite of cardiac death, target-vessel MI, and TVR.
Results: The mean age of patients was 62.1 ± 11 years. The mean length of total stents used was 75.1 ± 16.4 mm (60-150). During the median follow-up of 74.7 months (interquartile range: 58-96), the rates of cardiac death, MI, TLR, and TVR were: 5.8% (n = 16), 6.2% (n = 17), 27.3% (n = 81), and 30% (n = 89), respectively. The MACE rate was 34%. Definite and probable stent thrombosis occurred in 10 patients (3.6%).
Conclusion: The long-term follow-up of patients with FMJ is acceptable especially in regards to hard endpoints (death and MI) given the complexity of lesions treated. The high MACE rate was driven mainly by TVR. The availability of newer-generation DES and bioabsorbable scaffolds may improve these results. © 2014 Wiley Periodicals, Inc.
Keywords: drug-eluting stents; full-metal jacket; long-diffuse lesions.
© 2014 Wiley Periodicals, Inc.
Similar articles
-
Assessment of efficacy and safety of combining "paclitaxel" eluting balloon and "limus" eluting stent in the same lesion.J Interv Cardiol. 2013 Jun;26(3):259-63. doi: 10.1111/j.1540-8183.2013.12010.x. Epub 2013 Feb 4. J Interv Cardiol. 2013. PMID: 23373592
-
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13. JACC Cardiovasc Interv. 2013. PMID: 24239202 Clinical Trial.
-
Comparison of mid-term clinical outcomes between "complete full-metal jacket strategy" versus "incomplete full-metal jacket strategy" for diffuse right coronary artery stenosis with drug-eluting stents.J Cardiol. 2017 Jun;69(6):823-829. doi: 10.1016/j.jjcc.2016.09.014. Epub 2016 Nov 2. J Cardiol. 2017. PMID: 27816320
-
Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies.JACC Cardiovasc Interv. 2013 Jul;6(7):687-95. doi: 10.1016/j.jcin.2013.03.012. Epub 2013 Jun 14. JACC Cardiovasc Interv. 2013. PMID: 23769650 Review.
-
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis.J Cardiovasc Med (Hagerstown). 2019 May;20(5):321-326. doi: 10.2459/JCM.0000000000000767. J Cardiovasc Med (Hagerstown). 2019. PMID: 30664538 Review.
Cited by
-
Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention.Clin Drug Investig. 2017 Feb;37(2):105-120. doi: 10.1007/s40261-016-0472-1. Clin Drug Investig. 2017. PMID: 27766510 Review.
-
Comparison of mid-term clinical outcomes between on-label and off-label use of rotational atherectomy.Heart Vessels. 2017 May;32(5):514-519. doi: 10.1007/s00380-016-0899-6. Epub 2016 Oct 5. Heart Vessels. 2017. PMID: 27709324
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous